FDA approves relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer

The FDA has granted approval for the combination of relacorilant and nab-paclitaxel to treat adult patients with platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already received one to three prior systemic regimens.

The supporting trial enrolled a non‑biomarker‑selected population, meaning patients did not need any specific molecular test to be eligible as long as they met the standard inclusion criteria.

Dr. Alexander B. Olawaiye highlighted the clinical significance of the decision, noting that the regimen offers a new therapeutic option for patients who have previously been treated with bevacizumab and other standard therapies.

This approval adds a targeted approach for a disease area with limited treatment choices, potentially improving outcomes for a group of patients with few alternatives.